Lutoral

Quick links to important sections

Lutoral

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lutoral

Property Description
Active ingredient Chlormadinone acetate
Form Tablet (Oral formulation)
Pharmacological class Synthetic Progestogen
General Purpose Hormonal regulation
Origin Synthetic, Steroidal

What Type of Medicine is Lutoral? (Identity and Classification)

Lutoral is a pharmaceutical product whose active ingredient is Chlormadinone acetate, classified pharmacologically as a synthetic progestogen. It belongs to the unique Pregnadien derivatives subgroup of hormone therapy agents, designated by the WHO Anatomical Therapeutic Chemical (ATC) code G03DB06. As a synthetic compound, it is structurally modified to enhance its oral bioavailability and specific effects in the body, which sets it apart from naturally occurring progesterone. Lutoral is defined as a single-entity product, meaning its function is specifically centered on providing progestogenic activity to the body, a mechanism clinically recognized for regulating the menstrual cycle.

Composition and Form: The Active Ingredient Chlormadinone Acetate

The medicine is supplied as an oral formulation in the form of a tablet, which establishes the oral route of administration. The tablet primarily contains the pure Chlormadinone acetate substance, which functions as a small molecule that is readily absorbed into the bloodstream. The remainder of the composition consists of inert solid oral excipients necessary to create the physical structure, stability, and proper dissolution profile of the tablet. The synthesis of this compound results in a potent steroidal structure, designed for consistent systemic hormonal delivery.

General Purpose: Progestogenic and Antiandrogenic Action

The general function of Lutoral is to provide targeted progestogenic activity within the body, acting as a potent progesterone receptor agonist. This mechanism allows the drug to mimic and amplify the effects of natural progesterone, thereby contributing to the regulation of hormone-sensitive systems. Furthermore, Chlormadinone acetate possesses significant secondary antiandrogenic activity, acting as a partial antagonist at the androgen receptor. This dual-action profile is a key differentiating feature, allowing the compound to mildly counteract the effects of androgens (male hormones), providing the basis for its general therapeutic role in managing sensitive hormonal balances where androgen opposition is beneficial.

What side effects are possible with Lutoral?

Possible Side Effects and Safety Information

The safety profile of Chlormadinone acetate (Lutoral) is defined by officially documented adverse reactions classified by frequency and a set of serious, duration-dependent risks.


Officially Documented Adverse Reactions

The most frequently reported effects are classified as Common (affecting up to 1 in 100 people) in regulatory documentation. These primarily include headache, intermenstrual bleeding (spotting, breakthrough bleeding), and breast pain or tenderness. Adverse reactions are grouped by the affected body system, such as Reproductive System and Breast Disorders and Nervous System Disorders.


Serious Safety Considerations

The regulatory label documents specific serious adverse reactions. The risk of Meningioma, a type of tumor, has been established and is explicitly linked to the cumulative dose and prolonged duration of Chlormadinone acetate use, particularly at higher doses. Other serious risks associated with hormonal agents include Venous and Arterial Thromboembolic Events (e.g., Deep Vein Thrombosis) and Hepatic Neoplasms (liver tumours).


Safety Constraints and Restrictions

Official prescribing information includes specific limitations on use. Chlormadinone acetate is contraindicated and must not be used in individuals with a current or past history of meningioma, in those with severe hepatic disease, or in the presence of established risk factors for thromboembolism. These absolute constraints define the safety framework for the medicine's use, ensuring alignment with official regulatory review findings.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose with Lutoral (chlormadinone acetate) primarily as an exacerbation of known side effects, which are generally considered mild and transient.

Documented Overdose Presentations

Symptoms reported in cases of overdosage are generally related to central nervous system and reproductive effects, and may include:

  • Drowsiness (Somnolence)
  • Dizziness
  • Euphoria
  • Dysmenorrhoea (painful menstruation)

In some cases, the recurrence or persistence of these undesirable effects at the standard dosage may be an indication that the dose is too high for the individual, requiring an adjustment.

Emergency Actions and Management

In the event an accidental overdose is taken, the official guidance is to consult with your doctor or pharmacist.

No specific antidote is required for the symptoms listed above. The recommended approach to managing an overdose is based on observation and, if necessary, the administration of appropriate symptomatic and supportive measures.

Since the symptoms of overdosage are often self-limiting, they typically resolve spontaneously when the dosage is reduced or if the timing of administration is adjusted (e.g., taking the dose at night). Reduction of the prescribed dose is the most common management step described when mild overdose symptoms persist.

Therapeutic Uses of Lutoral

Lutoral (Chlormadinone acetate) is commonly used to provide symptomatic relief and supportive therapeutic benefit across key domains of women's health, focusing on stabilizing hormonal imbalances.

It is used to address specific therapeutic needs in hormonal management.

Cycle Regulation, Pain, and Androgen Relief

Used in situations involving certain distressing symptoms. Key indications include managing cycle disorders such as secondary amenorrhea (absent periods), menorrhagia (heavy bleeding), and severe dysmenorrhea (menstrual pain), alongside androgen-driven symptoms like acne vulgaris and hirsutism (excessive hair growth). It is relevant when supportive symptom management is appropriate and conditions present with systemic or localized discomfort.

In clinical settings, Lutoral is often used during phases when symptoms become more noticeable. This application supports the patient during difficult episodes by easing distress and assists with maintaining functional stability of the menstrual cycle and skin health, relevant for managing symptoms that interfere with daily comfort.

“It is commonly used when short-term symptomatic assistance is needed to address conditions involving episodic or fluctuating manifestations like hormone deficiencies.”


Quick Fact: Relief for Androgen-Related Symptoms

Lutoral is applied across domains where additional symptomatic support is needed to address dermatological issues and unwanted hair growth related to heightened physiological activity.

Regulatory References

  1. Malta Medicines Authority regarding Chlormadinone acetate

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Lutoral (Chlormadinone Acetate)

This medicine is primarily intended for use in adult women who meet specific medical criteria. Eligibility is strictly defined by regulatory documents based on physiological status and underlying health conditions.

Populations That Must NOT Use This Medicine

The most critical exclusions are defined as contraindications in official labeling:

  • Pregnancy Status: Use is contraindicated if the patient has a known or suspected pregnancy. The medicine is generally not recommended for use during delivery.
  • Severe Comorbidity: Contraindications may include severe liver disease or tumors, and use with specific Hepatitis C drug combinations.

Populations Requiring Restricted or Cautious Use

Certain groups require a careful medical assessment before use, meaning administration is not recommended or requires caution:

  • Lactation: Use is not recommended for women who are breastfeeding.
  • Liver Function: Patients with a known liver disorder require cautious consideration.
  • Prior Reactions: Individuals with a history of allergic reactions (hypersensitivity) to Lutoral or its components.
  • Meningioma: Caution is required in patients with a history of or current meningioma, which is an officially documented risk factor.

What should I know about interactions with other medicines?

Interactions with other medicines and products

It is important for patients taking Lutoral (chlormadinone acetate) to be fully transparent with their healthcare providers about all other products they are using. The potential for drug interactions exists with a variety of substances, which may lead to either an enhancement or diminution of Lutoral's expected effects.

Documented Interaction Profile

Product Category
Other Prescription Medicines
Over-the-Counter (OTC) Medicines
Dietary Supplements

Mechanistically, the metabolism of hormonal products like Lutoral may be accelerated or inhibited by co-administered agents. Drugs that induce hepatic enzymes, particularly those within the cytochrome P450 system, can potentially reduce the plasma concentration and effectiveness of chlormadinone acetate. Conversely, agents that inhibit hepatic enzymes may increase its concentration, leading to a potentially elevated risk of adverse effects. However, official regulatory documents do not list specific medicines by name that are strictly contraindicated or require timed spacing, instead emphasizing a broad caution for all medicinal products and supplements. Consistent discussion with a doctor or pharmacist is advised to review the complete medication profile and manage any potential interactions.

Mechanism of Action

Lutoral, containing Chlormadinone Acetate (CMA), functions as a synthetic steroid with multiple molecular interactions. Its primary biological target is the progesterone receptor (PR), where it acts as a full agonist. Binding to the intracellular PR initiates receptor dimerization and translocation to the nucleus, modifying the transcription of progesterone-responsive genes.

Concurrently, CMA exhibits antagonist activity at the androgen receptor (AR), blocking the binding of endogenous androgens. It also reduces the activity of cutaneous 5alpha-reductase, an enzyme that catalyzes the conversion of testosterone to its more potent derivative, dihydrotestosterone.

At the systemic level, CMA provides negative feedback to the hypothalamic-pituitary system. This cascade suppresses the secretion of gonadotropins, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), thereby inhibiting the steroidogenesis of ovarian and adrenal androgens and modulating the follicular maturation process. Intracellularly, its progestational effects induce changes in endometrial architecture and cervical mucus viscosity.

Dosage and Administration Information

How to Use Lutoral (Chlormadinone Acetate)

Lutoral is administered orally as a tablet. The official instructions for use mandate strict adherence to the prescribed daily dosage and timing, especially in the context of assisted reproductive technologies (ART).

Official Administration Guidelines (Adults)

Guideline Element Official Instruction
Route of Administration Oral (by mouth)
Dosing Schedule 1 to 6 tablets (2 to 12 mg) per day
Frequency Administer the total daily dose in 1 to 3 divided doses
Timing (ART Cycles) Fresh Embryo Transfer: From the time of egg retrieval to the day of embryo transfer. Frozen Embryo Transfer: From the time the endometrium gets thick enough to the day of embryo transfer.

Procedural Steps

  1. Take the prescribed dose of tablets orally as directed by your healthcare provider. The maximum recommended daily dose is 12 mg.
  2. Administer the dose(s) in a consistent manner, daily.
  3. Missed Dose Rules: If a dose is missed, take it as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and continue with the regular schedule. Never take two doses at one time to make up for a missed dose.
  4. Do not stop taking the medication unless explicitly instructed to do so by your doctor.

Following the exact dosing and procedural schedule is mandatory to maintain the therapeutic regimen. The dosing and duration are highly context-specific, particularly when used for menstrual cycle adjustment or in preparation for embryo transfer, requiring close coordination with the official treatment protocol.

Recent Clinical Evidence

Evidence for Use in Menstrual Pain (Dysmenorrhea) and Cycle Stability

Research has explored the active ingredient in Lutoral for conditions characterized by fluctuating or episodic manifestations, such as severe menstrual pain (dysmenorrhea) and cycle irregularities. Studies used in research exploring how symptoms change over time often took the form of Randomized Controlled Trials (RCTs) that monitored outcomes related to physical discomfort, specifically changes in patient-reported outcomes describing perceived discomfort and the frequency of pain medication intake.

It is important to note that the research contributes to the broader evidence landscape primarily when the active ingredient was associated with the combination product (along with an estrogen component). For the single-entity Lutoral product, the evidence is limited regarding dedicated, large-scale studies specifically addressing severe menstrual pain or cycle irregularities when the drug is used alone. Long-term effects are not fully established, meaning the sustained durability of these observed patterns beyond the initial research period requires more information.


Evidence for Use in Androgen-Driven Symptoms (Acne and Hirsutism)

The active ingredient was studied for outcomes related to systemic or functional imbalance that characterize androgen-driven symptoms, such as acne and excessive hair growth (hirsutism). Researchers monitored objective measurements, such as the total count of acne lesions, and subjective measures, like global assessment scores for skin appearance.

Research describes changes measured during the study period that required observation over intermediate follow-up periods (typically six to twelve months). The research on the specific antiandrogenic profile of the single-entity Lutoral product remains limited compared to the volume of dedicated, large-scale RCTs on the combination product. Furthermore, data for certain groups remain insufficient, especially for patients experiencing more severe forms of these conditions.


Evidence Context in Specialized Settings (Luteal Phase Support)

In a separate, highly specialized research scenario, the active ingredient was evaluated in women undergoing Assisted Reproductive Technology (ART) procedures. These studies monitored outcomes specific to fertility treatment, such as live birth rates and clinical pregnancy rates. Research reported comparability between the measured rates for these critical outcomes and those found when patients used other standard hormonal protocols. This specialized evidence provides context but not individual predictions for general use.

Key Studies & References

  1. Malta Medicines Authority Assessment Report for Chlormadinone Acetate

Frequently Asked Questions (FAQ)

Common questions about Lutoral (FAQ)

Q: How quickly does Lutoral start working after I begin taking it?

A: The active ingredient, chlormadinone acetate, is rapidly and almost completely absorbed into the body after oral administration. According to general pharmacokinetic data (how the drug moves through the body), stable concentrations of the medicine in the bloodstream are typically reached around day 7 of continuous administration.

Q: Is it possible to take Lutoral for a very long time?

A: Official warnings link the serious risk of Meningioma (a type of tumor) to the cumulative dose and prolonged duration of using the active ingredient, especially at higher doses. While there is no defined maximum treatment duration, official documents advise physicians to weigh this safety consideration carefully when considering long-term use.

Q: Can Lutoral cause unexpected weight changes?

A: Official safety documents for the active ingredient or related hormonal products note that some patients report weight gain as a potential side effect. Clinical studies on the active ingredient have sometimes shown that mean body weight remained stable over intermediate treatment periods.

Q: Will Lutoral make me feel dizzy or affect my ability to drive?

A: The most frequently reported effect on the nervous system is headache, which is listed as a common side effect in official safety documents. Potential central nervous system (CNS) effects that are described in official documents, such as headache, are noted for their potential impact on activities requiring alertness, such as driving or operating machinery.

Q: Is there a risk of interaction between Lutoral and birth control pills?

A: Since Lutoral contains a synthetic progestogen, using it concurrently with other hormonal products, such as birth control pills or other progestogens, may alter the overall effectiveness of either medication. Regulatory documents emphasize the importance of communicating with your healthcare provider about all hormonal medicines currently being used.

Q: Does alcohol consumption affect how Lutoral works?

A: Specific regulatory documents generally do not list a direct chemical interaction between alcohol and the active ingredient. However, official guidance for hormonal agents often notes that heavy drinking may indirectly affect the medicine's effectiveness or adherence to the dosing regimen.

Q: Are there any herbal supplements that interact with Lutoral?

A: Yes, official documents specifically caution that herbal remedies that induce hepatic enzymes (which help the liver break down drugs) may reduce Lutoral’s concentration in the body. A well-known example of this type of enzyme inducer mentioned in regulatory texts is the herbal supplement St. John's wort.

Q: Is Lutoral considered safe for older adults?

A: Clinical experience is primarily documented in women of reproductive age, aligning with the drug's main uses. Use in patient groups outside of the primary indicated age range is described as requiring specific medical assessment.

Q: Can men use Lutoral, or is it only for women?

A: The drug is officially indicated for conditions primarily associated with women, such as menstrual disorders. However, the active ingredient is noted for its antiandrogenic properties (counteracting male hormones), and it has been studied in men for conditions like benign prostatic hyperplasia in some regulatory contexts.

Q: Can Lutoral affect blood pressure readings?

A: Official safety data lists serious risks including Venous and Arterial Thromboembolic Events (blood clots). Because of the known association between hormonal agents and cardiovascular risk factors, official guidance notes that medical monitoring of blood pressure may be appropriate, particularly for patients with existing high-risk cardiovascular conditions.

Q: Can Lutoral be taken on an empty stomach?

A: Yes, official regulatory information for the active ingredient generally states that the tablet can be taken with or without food. Taking it with a meal, sometimes the evening meal, may be suggested to improve consistency and reduce stomach upset.

Q: What if I'm taking multiple prescriptions; can I still take Lutoral?

A: Some medicines, such as certain antibiotics or anticonvulsants, can affect the liver enzymes that process Lutoral. Drugs that speed up this process may reduce Lutoral's effectiveness, while those that slow it down may increase its concentration. Official guidance emphasizes the importance of providing a physician with a complete list of all medications to allow for the management of potential interactions.

Q: Is it true that Lutoral can affect mood?

A: Yes, official regulatory documents or clinical data for the active ingredient may list effects on emotional well-being. Potential side effects noted can include changes in mood, such as mood swings, irritability, or depressive symptoms.

Q: What is the typical duration of treatment with Lutoral?

A: The duration is highly specific to the condition being treated. For cycle management, it may be administered for a fixed number of days each month. For Luteal Phase Support, the duration is tied directly to the Assisted Reproductive Technology (ART) cycle protocol as defined in regulatory texts.

Q: Are there any warning signs I should look for when starting Lutoral?

A: Official documents highlight symptoms related to the most serious risks, specifically Venous Thromboembolic Events (blood clots). Symptoms such as unexplained pain or swelling in the legs, or sudden shortness of breath, are described in official documents as warranting immediate medical attention.

Q: Can people with kidney problems use Lutoral?

A: Official contraindications for the active ingredient do not typically include kidney impairment (renal disease). However, the medicine is strictly contraindicated (must not be used) in individuals with severe hepatic (liver) disease, as the liver is the primary site for processing the drug.

Q: What is the risk of serious side effects with Lutoral?

A: The official safety profile documents serious adverse effects, including Meningioma and Thromboembolic Events (blood clots). While these events are statistically considered rare, they are listed as significant safety considerations in official prescribing information due to their potential severity.

Q: How do I know if Lutoral is actually working for my condition?

A: Regulatory documents describe the intended clinical response (e.g., changes in menstrual pain, cycle regulation, or support of the luteal phase in ART). Clinical success is typically measured by the resolution or improvement of the targeted symptoms as assessed through medical follow-up.

Q: Does Lutoral affect sleep patterns?

A: The side effect profile for the active ingredient or related hormonal products may include sleep disturbances or insomnia among the documented adverse reactions. If sleep issues persist, a medical review is advised.

Q: Is Lutoral the kind of drug that needs to be stopped slowly?

A: Official documents strongly state that the medicine should not be stopped unless explicitly instructed by a physician. The need for a gradual reduction, or tapering, is not a universal rule but may be required depending on the specific medical condition being treated and the duration of use.

Q: Has Lutoral been reviewed by major international health bodies?

A: Yes, the active ingredient in Lutoral, Chlormadinone acetate, is reviewed and regulated by major governmental health bodies. This includes European agencies like the EMA and national regulatory bodies like the MHRA (UK) and the TGA (Australia), whose official documents govern its prescription.

Q: Do the side effects of Lutoral get better over time?

A: Common side effects like headache or breast tenderness are often described as transient (temporary) in official sources. Official sources note that many common side effects are transient, suggesting that the body may adjust as treatment continues.

Q: Can Lutoral be used during pregnancy or while breastfeeding?

A: Use is contraindicated (must not be used) during known or suspected pregnancy due to the potential for fetal harm. Official guidance also advises against using the medicine during breastfeeding/lactation, as the active substance may be excreted into breast milk.

Q: Is Lutoral an addictive drug?

A: Official drug documents from regulatory authorities do not include any warnings or information regarding the potential for dependence, addiction, or abuse for Chlormadinone acetate.

Q: Are there any specific tests I need before starting Lutoral?

A: Regulatory guidance advises that a complete medical and family history should be taken before starting treatment. Specific preliminary tests, such as a pregnancy test or general clinical examination, may be required depending on the medical context.

Q: Does Lutoral affect fertility?

A: The drug's mechanism of action involves suppressing the secretion of hormones necessary for ovulation, meaning it can inhibit ovulation and thus affect fertility while the medicine is being taken. It is also studied specifically for use in Assisted Reproductive Technology (ART) to support pregnancy.

Q: What are the long-term effects of taking Lutoral?

A: The long-term effects are partially established by regulatory documents which warn of a duration- and dose-dependent serious risk of Meningioma. For other non-oncological effects, research notes that long-term effects are not fully established beyond the scope of initial studies.

Q: Is there a known difference in effect between the tablet and capsule form of Lutoral?

A: Lutoral is officially provided and studied as an oral tablet formulation, which is the basis for all regulatory approvals and clinical data. Official documents do not address or compare the effects of an alternative capsule form.

Q: Why is Lutoral sometimes given as a combination therapy?

A: The active ingredient is frequently studied and used in combination with an estrogen to balance the effects of both hormones. This combination strategy is typically used for contraception or to manage certain hormone-sensitive conditions, leveraging the drug's antiandrogenic properties.

Q: Are there any foods I should strictly avoid when taking Lutoral?

A: Official regulatory documents and patient information leaflets generally do not list any specific foods that must be strictly avoided when taking Lutoral. You can typically maintain your normal diet.

Q: Is Lutoral available over-the-counter in any country?

A: Lutoral is classified as a prescription-only medicine in all regions where it is officially regulated and marketed by major health authorities. It is not available for purchase over-the-counter.

Q: Do official sources mention any long-term monitoring required with Lutoral?

A: Yes, due to the potential for duration-dependent serious risks like Meningioma, official guidance recommends regular medical monitoring and check-ups, especially for individuals using the drug for prolonged periods.

How should Lutoral be stored and disposed of?

Storage and Disposal Information

Official regulatory documentation outlines specific requirements for storing and disposing of Lutoral to maintain its stability and ensure safety.

Requirement Details
Temperature Store at room temperature, generally below 30 C (86 F).
Protection Keep away from direct sunlight, heat, and moisture. Do not refrigerate or freeze.
Packaging Retain the medicine in its original PTP sheet (blister pack) until the time of use.
Child Safety Keep Lutoral securely out of the sight and reach of children at all times.
Disposal The remainder of the medicine must be discarded immediately after the required use is complete. Disposal should follow the specific procedures advised by a dispensing pharmacy or medical institution, and the medicine must not be flushed or thrown into general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lutoral found in:

A-Z Index: